Biotricity Q1 FY2024 revenue up 46.9% to $3.0M; net loss improves 28% to $3.6M

BIOTRICITY INC.

2024-Q1 EPS reported -$0.07 revenue$3,020,765

Revenue $3.02M, up 46.9% YoY; recurring technology fees $2.8M, up 47% YoY.
Gross margin improved to 63.5% from 59.6%; SG&A reduced 22% to $3.5M.
Net loss improved 28% to $3.6M ($0.069 per share) from $5.0M ($0.098 per share).
Customer retention ~98%; expanding sales network across 35 states with >2,500 cardiologists.
Management focuses on path to profitability and AI development with Amazon and Google.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOTRICITY INC. reported first quarter fiscal 2024 ended June 30, 2023 results: revenue $3.02 million, net income $3.6 million, EPS $0.069 per share.

Period: first quarter fiscal 2024 ended June 30, 2023
Revenue: $3.02 million
Net income: $3.6 million
EPS: $0.069 per share
Result: reported results

Exact text from the filing

of subscription revenue, robust gross margins, and, over time, the establishment of a solid free cash flow model.” Q1-FY24 Financial Highlights ● Revenue increased 46.9% to $3.02 million compared with $2.06 million in Q1 FY24 ● Gross profit percentage was 63.5% for the three months ended June 30, 2023, as compared to 59.6% in the corresponding prior year

View on SEC.gov

Browse all earnings releases →

BIOTRICITY INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-029242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.